Martine Rothblatt is the founder of United Therapeutics and her team developed the pulmonary hypertension medication, Remodulin. Now her ambition is to tackle the organ shortage in America with technology and genetic engineering. Here is an article about how she is putting her goal into action and what it could mean for the future of transplantation.
What are your thoughts about what she is trying to accomplish?
Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.